{
    "2020-12-30": [
        [
            {
                "time": "",
                "original_text": "【健帆生物 | 年报预告点评】业绩超预期，预计肾科维持高增长，肝科持续回暖【安信医药马帅团队】",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "年报预告",
                        "业绩超预期",
                        "肾科高增长",
                        "肝科回暖"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "600亿市值健帆生物股价连震荡2日 毛利率追贵州茅台",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "600亿市值",
                        "股价震荡",
                        "毛利率",
                        "贵州茅台"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "财务指标"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "600亿医疗股暴跌，是谎言还是恶意中伤",
                "features": {
                    "keywords": [
                        "600亿医疗股",
                        "暴跌",
                        "谎言",
                        "恶意中伤"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【健帆生物 | 年报预告继续强推】业绩超预期，预计肾科维持高增长，肝科持续回暖【安信医药马帅团队】",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "年报预告",
                        "业绩超预期",
                        "肾科高增长",
                        "肝科回暖"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "医疗器械"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}